Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.

By S. Hadziyannis, N. Tassopoulos, E. Heathcote, Ting Chang, G. Kitis, M. Rizzetto, P. Marcellin, Seng‐Gee Lim, Z. Goodman, Jia Ma and 4 more. Gastroenterology, 2006

882 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/b14099186f9839ede53140f61246f8e4488d6c19

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Hepatology

Citations in the corpus

WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. (2015, background): “…documented in studies of paired liver biopsies from patients with chronic hepatitis C who achieved sustained viral eradication (Poynard et al. 2002; Shiratori et al. 2000) and patients with chronic hepatitis B who received long-term antiviral therapy (Chang et al. 2010; Hadziyannis et al. 2006).”
EASL Clinical Practice Guidelines: management of chronic hepatitis B. (2009, background): “…adefovir or telbivudine, a virological response at 24 or 48 weeks (undetectable HBV DNA in a real-time PCR assay) is associated with a lower incidence of resistance, i.e. an improved chance of maintained virological response, and HBe seroconversion in HBeAg-positive patients [41] [46] [57] (B1).”
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. (2012, background): “Adefovir is less efficacious and more expensive than tenofovir, engendering higher rates of resistance [70,85,100].”
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update (2012, background): “49 % of those with HBV DNA [200 IU/mL) during 192 weeks of ADV treatment in HBeAg-negative patients [124].”
Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B (2010, background): “Two smaller cohorts of nucleoside-naive, HBeAg-negative CHB patients treated with adefovir were followed for 4 (n 1⁄4 22) or 5 years (n 1⁄4 24).(26) In this report, 12 of 22 patients (55%) treated for 4 years and 17 of 24 patients (71%) treated for 5 years demonstrated improvements in the Ishak fibr”
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update (2008, background): “5 mg/dl) was reported in 3% of patients when therapy was extended to 5 years [80].”
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. (2015, background): “HBV Prolonged treatment with antiviral therapy is associated with resolution of liver fibrosis and regression of liver cirrhosis [269–271].”